FCN2: Potential Drug Target and Biomarker (G2220)

Target Name: FCN2

NCBI ID: G2220

FCN2

FCN2: Potential Drug Target and Biomarker

FCN2 (Ficolin-beta), a protein that belongs to the family of beta-tubulin substrate-binding protein (BTB) and is expressed in a variety of tissues including muscle, heart, brain, and stem cells, has been identified as a potential drug target and biomarker. The beta-tubulin complex is a protein complex that plays a critical role in cell division and growth, and is composed of several subunits that can interact with each other to regulate the movement of cells in the cytoskeleton. FCN2 is one of the subunits that belong to the alpha subunit class of the beta-tubulin complex and is expressed in a variety of tissues.

FCN2 has been shown to play a role in the regulation of cell division and growth, and is expressed in tissues that are constantly undergoing cell division, such as muscle and heart cells. It has also been shown to interact with several other proteins, including the transcription factor p21 (AP1), which is known to play a role in the regulation of cell growth and division.

In addition to its role in cell division and growth, FCN2 has also been shown to play a role in the regulation of cell survival. Studies have shown that FCN2 can interact with the protein Bcl-2 (B cell lymphoma 2), which is known to play a role in the regulation of cell survival and proliferation. The interaction between FCN2 and Bcl-2 has been shown to contribute to the regulation of cell survival and the development of cancer.

As a potential drug target, FCN2 has been shown to be involved in a variety of signaling pathways, including the regulation of cell division, cell survival, and the regulation of the cytoskeleton. It has also been shown to play a role in the development of cancer, and is often overexpressed in cancer cells. Therefore, FCN2 may be an attractive target for small molecule inhibitors that can modulate its function and have the potential to be used in cancer treatment.

In addition to its potential as a drug target, FCN2 has also been identified as a potential biomarker for a variety of diseases, including cancer. The regulation of cell division and growth is a critical aspect of many diseases, including cancer, and FCN2 may be a useful biomarker for the detection and treatment of these diseases.

FCN2 has been shown to be expressed in a variety of tissues and cells, including muscle and heart cells, brain cells, and cancer cells. Therefore, FCN2 may be a useful biomarker for the detection and treatment of a variety of diseases, including cancer. For example, FCN2 has been shown to be overexpressed in a variety of cancer types, including breast, lung, and ovarian cancer. Therefore, FCN2 may be a potential target for small molecule inhibitors that can be used to treat these cancers.

In conclusion, FCN2 is a protein that has been shown to play a critical role in the regulation of cell division and growth, and is expressed in a variety of tissues. It has also been shown to interact with several other proteins, including the transcription factor p21 and the protein Bcl-2. As a potential drug target and biomarker, FCN2 may be an attractive target for small molecule inhibitors that can modulate its function and have the potential to be used in cancer treatment. Additionally, FCN2 may be a useful biomarker for the detection and treatment of a variety of diseases, including cancer.

Protein Name: Ficolin 2

Functions: May function in innate immunity through activation of the lectin complement pathway. Calcium-dependent and GlcNAc-binding lectin. Enhances phagocytosis of S.typhimurium by neutrophils, suggesting an opsonic effect via the collagen region

The "FCN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets